Skip to main
AVBP

AVBP Earnings Dates & Reports

AVBP Most Recent Earnings

Report Date
Period EndingQ4 2025
Est. EPS-$0.86
Actual EPS-$0.78
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

AVBP Earnings per Share (EPS) History

Signup for full access
Browse free

AVBP Latest Earnings

The value each AVBP share was expected to gain vs. the value each share gained.

AVBP reported its most recent earnings on for Q4 2025, posting earnings per share (EPS) of -$0.78. This exceeded analysts' expectations of -$0.86 by 9.30%, marking a Beat.

For comparison, ArriVent Biopharma Inc reported EPS of $0 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.90.

AVBP Earnings History

Earnings
Est. EPSActual EPSSurprise
Q1 2026
-$0.90
Q4 2025
-$0.86-$0.78-9.30%
Q3 2025
-$0.78-$0.83+6.41%
Q2 2025
-$0.71-$0.90+26.76%

AVBP Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the ArriVent Biopharma Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

AVBP Earnings FAQs

AVBP last reported earnings on Mar 5, 2026 for Q4 2025, posting an EPS of -$0.78, which Beat the estimate of -$0.86 by 9.30%.

For Q4 2025, AVBP reported an EPS of -$0.78, exceeding analysts' estimate of -$0.86 by 9.30%.

For Q4 2025, AVBP Beat expectations with an actual EPS of -$0.78 vs. an estimated EPS of -$0.86.

Following the last earnings report on Mar 5, 2026, AVBP's stock price moved — from — to —.

The next AVBP earnings call is scheduled for May. 11, 2026, where executives will discuss financial results and outlook.

ArriVent Biopharma Inc (AVBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.